Dr. Lee, Te-Chang 's publons link picture

Dr. Lee, Te-Chang

Adjunct Research Fellow
  • 02-27899145 (Lab) (Room No: N247)
  • 02-26523055 (Office)
  • 02-27829142 (Fax)

Specialty:
  • Genetic and Molecular Toxicology
  • Cancer Biology
  • Pharmacology
  • Biobank

Education and Positions:
  • Ph.D. National Taiwan University


Dr. Lee, Te-Chang 's
Publications

  1. Chen CW, Wu MH, Chen YF, Yen TY, Lin YW, Chao SH, Tala S, Tsai TH, Su TL, (Lee TC)* A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells. NEOPLASIA 18(4), 199-212 (2016) [JCR] [WOS]
  2. Lai KC, Liu CJ, Lin TJ, Mar AC, Wang HH, Chen CW, Hong ZX, (Lee TC)* Blocking TNF-alpha inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells. Cancer letters 370(2), 207-15 (2016) [JCR] [WOS]
  3. Kuo HH, Kakadiya R, Wu YC, Su TL, (Lee TC), Lin YW, Yih LH Derivatives of 6-cinnamamido-quinoline-4-carboxamide impair lysosome function and induce apoptosis. Oncotarget 7(25), 38078-38090 (2016) [JCR] [WOS]
  4. Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, Tseng LM, (Lee TC), Chen KF, Liu CY, Chiu HC, Shiau CW Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Scientific reports 6, 28888 (2016) [JCR] [WOS]
  5. Wu MM, Lee CH, Hsu LI, Cheng WF, (Lee TC), Wang YH, Chiou HY, Chen CJ Effect of heme oxygenase-1 gene promoter polymorphism on cancer risk by histological subtype: A prospective study in arseniasis-endemic areas in Taiwan. International journal of cancer 138(8), 1875-86 (2016) [JCR] [WOS]
  6. Cheng LH, Hung KF, (Lee TC), Huang CY, Chiu WT, Lo JF, Huang TF Mitochondrial co-chaperone protein Tid1 is required for energy homeostasis during skeletal myogenesis. Stem cell research & therapy 7(1), 185 (2016) [JCR] [WOS]
  7. Chang CW, Chen YS, Chen CC, Chan IO, Chen CC, Sheu SJ, Lin TW, Chou SH, Liu CJ, (Lee TC), Lo JF Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and src activity using an active component of antrodia cinnamomea mycelia. Oncotarget doi: 10.18632/oncotarget.12194 (2016) [JCR] [WOS]
  8. Warpman Berglund U, Sanjiv K, Gad H, Kalderen C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, Chernobrovkin A, Manoilov A, Pateras IS, Rasti A, Jemth AS, Almlof I, Loseva O, Visnes T, Einarsdottir BO, Gaugaz FZ, Saleh A, Platzack B, Wallner OA, Vallin KS, Henriksson M, Wakchaure P, Borhade S, Herr P, Kallberg Y, Baranczewski P, Homan EJ, Wiita E, Nagpal V, Meijer T, Schipper N, Rudd SG, Brautigam L, Lindqvist A, Filppula A, (Lee TC), Artursson P, Nilsson JA, Gorgoulis VG, Lehtio J, Zubarev RA, Scobie M, Helleday T Validation and development of MTH1 inhibitors for treatment of cancer. Annals of oncology : official journal of the European Society for Medical Oncology 27(12), 2275-2283 (2016) [JCR] [WOS]
  9. Bujňáková Z, Baláž P, Makreski P, Jovanovski G, Čaplovičová M, Čaplovič L, Shpotyuk O, Ingram A, (Lee TC), Cheng JJ, Sedlák J, Turianicová E, Zorkovská A Arsenic sulfide nanoparticles prepared by milling: properties, free-volume characterization, and anti-cancer effects. Journal of Materials Science 50(4), 1973-1985 (2015) [JCR] [WOS]
  10. Liao YC, Chen YF, (Lee TC)* Increased susceptibility of H-Ras(G12V)-transformed human urothelial cells to the genotoxic effects of sodium arsenite. Archives of toxicology 89(11), 1971-9 (2015) [JCR] [WOS]